Inhibin/activin-betaC subunit in human endometrial adenocarcinomas and HEC-1a adenocarcinoma cell line

In Vivo

Volumn 24, Issue 5, 2010, Pages 695-698

  Käufl, Stephanie D ^a   Makovitzky, Josef ^b   Kuhn, Christina ^a   Kunze, Susanne ^a   Jeschke, Udo ^a   Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Endometrial carcinoma cell line; Endometrioid adenocarcinomas; HEC 1a; Immunofluorescence; Immunohistochemistry; Inhibin betaC

Indexed keywords

ACTIVIN; INHIBIN; INHIBIN SUBUNIT BETA C; INHIBIN SUBUNIT BETA E; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ARTICLE; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 78649253640     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L and Choe S: Activins and inhibins and their signaling. Ann NY Acad Sci 1035: 142-147, 2004.
2. de Kretser DM, Hedger MP, Loveland KL and Phillips DJ: Inhibins, activins and follistatin in reproduction. Hum Reprod Update 8: 529-541, 2002.
3. Xia Y and Schneyer AL: The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202: 1-12, 2009.
4. Hötten G, Neidhardt H, Schneider C and Pohl J: Cloning of a new member of the TGF-beta family: a putative new activin beta C chain. Biochem Biophys Res Commun 206: 608-613, 1995.
5. Fang J, Yin W, Smiley E, Wang SQ and Bonadio J: Molecular cloning of the mouse activin beta E subunit gene. Biochem Biophys Res Commun 228: 669-674, 1996.
6. Fang J, Wang SQ, Smiley E and Bonadio J: Genes coding for mouse activin beta C and beta E are closely linked and exhibit a liver-specific expression pattern in adult tissues. Biochem Biophys Res Commun 231: 655-661, 1997.
7. Vejda S, Cranfield M, Peter B, Mellor SL, Groome N, Schulte-Hermann R and Rossmanith W: Expression and dimerization of the rat activin subunits betaC and betaE: evidence for the ormation of novel activin dimers. J Mol Endocrinol 28: 137-148, 2002.
8. Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ and Risbridger GP: Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)- subunit. J Clin Endocrinol Metab 85: 4851-4858, 2000.
9. Weissenbacher T, Bruning A, Kimmich T, Makovitzky J, Gingelmaier A and Mylonas I: Immunohistochemical labeling of the inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines. J Histochem Cytochem 58: 751-757, 2010.
10. Mylonas I, Makovitzky J, Kunze S, Brüning A and Schiessl B: Inhibin-betaC subunit in normal and pathological human placental tissue. Syst Biol Reprod Med, 2010.
11. Mylonas I, Shabani N, Vogl J, Makovitzky J, Kunze S, Kuhn C, Schulze S, Friese K and Jeschke U: Inhibin/activin subunits are immunohistochemically expressed in complete and partial hydatidiform moles. Anticancer Res 27: 1995-2000, 2007.
12. Kimmich T, Bruning A, Kaufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K and Mylonas I: Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet 282: 185-191, 2010.
13. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H and Inokuchi K: Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 7: 15, 2009.
14. Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U and Friese K: Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: Analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45: 1304-1314, 2009.
15. Mylonas I: Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: prognostic significance and clinical implications. Eur J Cancer, 2010.
16. Brüning A, Makovitzky J, Gingelmaier A, Friese K and Mylonas I: The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem Cell Biol 132: 33-38, 2009.
17. Bergauer F, Bruning A, Shabani N, Blankenstein T, Juckstock J, Dian D and Mylonas I: Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines. J Mol Histol 40: 353-359, 2009.
18. Lau AL, Kumar TR, Nishimori K, Bonadio J and Matzuk MM: Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration. Mol Cell Biol 20: 6127-6137, 2000.
19. Hashimoto O, Tsuchida K, Ushiro Y, Hosoi Y, Hoshi N, Sugino H and Hasegawa Y: cDNA cloning and expression of human activin betaE subunit. Mol Cell Endocrinol 194: 117-122, 2002.
20. Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS and Friese K: Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 122: 461-471, 2004.
21. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V and Friese K: Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol Oncol 93: 92-97, 2004.
22. Mylonas I, Makovitzky J, Fernow A, Richter DU, Jeschke U, Briese V, Gerber B and Friese K: Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps. Arch Gynecol Obstet 272: 59-66, 2005.
23. Mylonas I, Makovitzky J, Hoeing A, Richter DU, Vogl J, Schulze S, Jeschke U, Briese V and Friese K: Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. Acta Histochem 108: 1-11, 2006.
24. Worbs S, Shabani N, Mayr D, Gingelmaier A, Makrigiannakis A, Kuhn C, Jeschke U, Kupka MS, Friese K and Mylonas I: Expression of the inhibin/activin subunits (-alpha, -betaA and - betaB) in normal and carcinogenic endometrial tissue: Possible immunohistochemical differentiation markers. Oncol Rep 17: 97-104, 2007.
25. Gold EJ, Zhang X, Wheatley AM, Mellor SL, Cranfield M, Risbridger GP, Groome NP and Fleming JS: betaA- and betaC-activin, follistatin, activin receptor mRNA and betaC-activin peptide expression during rat liver regeneration. J Mol Endocrinol 34: 505-515, 2005.
26. Gold E, Jetly N, O'Bryan MK, Meachem S, Srinivasan D, Behuria S, Sanchez-Partida LG, Woodruff T, Hedwards S, Wang H, McDougall H, Casey V, Niranjan B, Patella S and Risbridger G: Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo. Am J Pathol 174: 184-195, 2009.
27. Chabicovsky M, Herkner K and Rossmanith W: Overexpression of activin beta(C) or activin beta(E) in the mouse liver inhibits regenerative deoxyribonucleic acid synthesis of hepatic cells. Endocrinology 144: 3497-3504, 2003.
28. Vejda S, Erlach N, Peter B, Drucker C, Rossmanith W, Pohl J, Schulte-Hermann R and Grusch M: Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis 24: 1801-1809, 2003.
29. Wada W, Medina JJ, Kuwano H and Kojima I: Comparison of the function of the beta(C) and beta(E) subunits of activin in AML12 hepatocytes. Endocr J 52: 169-175, 2005.
30. Mellor SL, Ball EM, O'Connor AE, Ethier JF, Cranfield M, Schmitt JF, Phillips DJ, Groome NP and Risbridger GP: Activin betaC-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate. Endocrinology 144: 4410-4419, 2003.
31. Jeruss JS, Sturgis CD, Rademaker AW and Woodruff TK: Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res 63: 3783-3790, 2003.
32. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D and Sanicola M: Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 112: 575-587, 2003.
33. Razanajaona D, Joguet S, Ay AS, Treilleux I, Goddard-Leon S, Bartholin L and Rimokh R: Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res 67: 7223-7229, 2007.
34. Burdette JE and Woodruff TK: Activin and estrogen crosstalk regulates transcription in human breast cancer cells. Endocr Relat Cancer 14: 679-689, 2007.
35. Ramachandran A, Marshall ES, Love DR, Baguley BC and Shelling AN: Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett 275: 157-165, 2009.
36. Katik I, Mackenzie-Kludas C, Nicholls C, Jiang FX, Zhou S, Li H and Liu JP: Activin inhibits telomerase activity in cancer. Biochem Biophys Res Commun 389: 668-672, 2009.
37. Risbridger GP, Ball EM, Wang H, Mellor SL and Peehl DM: Reevaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer. Mol Cell Endocrinol 225: 73-76, 2004.
38. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ and Bradley A: Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360: 313-319, 1992.
39. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H and Bradley A: Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91: 8817-8821, 1994.